drug development

Pomerantz LLP investigates Disc Medicine ($IRON) for potential securities fraud after FDA rejected bitopertin drug application, triggering consecutive stock declines totaling over 28%.

Eli Lilly discontinuing select insulin products across EU/EEA by Q2 2027 due to commercial factors. Company's experimental retatrutide shows strong diabetes and weight-loss results.

Sarissa Capital deploys $5.79M in beaten-down biotech Biohaven despite 70% stock decline, betting on upcoming late-stage trial data and obesity candidate.

Novartis acquires SNV4818, a next-gen PI3Kα inhibitor, from Synnovation for $2B upfront plus $1B milestones to treat PIK3CA-mutated breast cancer.

$CRIS reports $19.4M Q4 earnings from one-time Erivedge sale; refocuses on PCNSL and CLL studies with $20.2M PIPE funding.

Soligenix's HyBryte study shows 48% response rate, nearly double the 25% threshold, with interim results expected this quarter.

Edgewise Therapeutics pursues two major drug candidates addressing unmet cardiac and muscular disease needs, with pivotal data expected through 2026.

Pfizer faces patent cliffs and COVID vaccine decline, betting on oncology and obesity drug pipelines to drive future growth amid acquisition integration challenges.

Deerfield Management increases Vera Therapeutics stake to $205.58M as kidney drug atacicept approaches July 7 FDA decision. Stock up 50% annually.

Incannex Healthcare receives FDA Fast Track Designation for IHL-42X sleep apnea treatment following positive Phase 2 results, plans optimized Phase 3 pathway.

BridgeBio reports positive Phase 3 results for BBP-418, showing 31-second improvement in walking tests. FDA submission expected H1 2026, potential U.S. launch late 2026/early 2027.

NASA awards Redwire $4 million for drug development in cancer, osteoporosis, and obesity. Shares rise 0.98% following funding announcement.

BridgeBio Pharma jumps 12.6% after William Blair initiates coverage with Outperform rating, citing accelerating product launches and robust rare-disease pipeline.

Protara Therapeutics reported $57.4M full-year 2025 loss while unveiling promising 68% response rate for TARA-002 in bladder cancer trial with funding extending to 2028.

Regencell Bioscience surged 21,000% despite zero revenue and no approved products, exemplifying speculative excess that investors should avoid.

Roche's petrelintide demonstrates 10.7% weight reduction in Phase II, positioning the amylin analog as a potential alternative to dominant GLP-1 drugs with favorable tolerability. Phase III trials planned.

Global GLP-1 receptor agonist market projected to grow from $70B in 2025 to $202B by 2033 at 12.78% annual rate, driven by obesity and diabetes prevalence.

United Therapeutics ($UTHR) stock rallies 3.98% after Phase 3 trial shows ralinepag reduces PAH worsening 55%, with FDA filing targeted for mid-2026.

Teva Pharmaceutical faces margin compression in generic drugs, pivoting toward complex generics and original drug development. Limited financial flexibility creates elevated execution risk.

Telix Pharmaceuticals expands its nuclear medicine presence with approved cancer-targeting drugs and 56% revenue growth, positioning itself as a key player in oncology diagnostics and therapeutics.